ReviewPediatric nephrology (Berlin, Germany)2014
Proteomics in acute kidney injury--current status and future promise.
Review in Pediatric nephrology (Berlin, Germany), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Article
- Urinary Hepcidin-25 Is Elevated in Patients That Avoid Acute Kidney Injury Following Cardiac Surgery.Canadian journal of kidney health and disease · 2018Article
- The nephrologist of tomorrow: towards a kidney-omic future.Pediatric nephrology (Berlin, Germany) · 2017Review
- Acute Kidney Injury.Annual review of medicine · 2016Review
- Proteome Analysis of Renoprotection Mediated by a Novel Cyclic Helix B Peptide in Acute Kidney Injury.Scientific reports · 2015Article
- Pediatric Nephrology in Primary Care: The Forest for the Trees.Frontiers in public health · 2015Article
- CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model.Transplantation · 2014Article
- Human miRNome profiling identifies microRNAs differentially present in the urine after kidney injury.Clinical chemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric acute kidney injury (AKI) is associated with increased morbidity, mortality and associated healthcare costs. Unfortunately, there are currently no effective therapies available, and this has been attributed in part to the late diagnosis of AKI. Therefore, significant efforts have been made to develop early diagnostic tools for AKI in the hope that early identification of renal injury will allow for effective therapeutic intervention. Different transcriptomic, proteomic and metabolomic technologies offer unbiased approaches to identifying novel biomarkers of AKI. This review will provide an overview of non-invasive pediatric AKI biomarkers. It will focus on unbiased technologies by using examples of biomarkers identified with "-omic" technologies and different methodological and implementation challenges will be highlighted. Finally, emerging proteomic techniques that may be applicable to biomarker discovery will be presented. Ultimately, the development of novel biomarkers of AKI may lead to the early diagnosis and effective therapeutic intervention of AKI to improve patient outcomes.
Indexed as
Identifiers
23595423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.